CClinicalTrials.gg
RecruitingNCT04952220USAKUpdated Jan 19, 2024

Exploratory Study of Ultrasound Signs of Native Septic Arthritis of the Knee

An observational study in Ultrasound Therapy; Complications, Septic Arthritis and Knee Arthritis, sponsored by Poitiers University Hospital. Recruiting at 7 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-19.

Sponsored by Poitiers University Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started Oct 2021; still recruiting 4 years 11 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Study summary

Primary objective: Description of ultrasound abnormalities seen in native septic arthritis of the knee during each visit.

Primary endpoint: Describe the ultrasound abnormalities observed on Day 0, Day 10, 6 weeks, 3 months, 6 months, during native septic arthritis of the knee.

Read the detailed description

Secondary Objectives:

  1. Search for poor prognostic factors in native septic arthritis of the knee.
  2. To look for an association between initial sonographic factors and the use of joint lavage.
  3. Look for associations between sonographic signs and clinico-radio-biologic factors at each visit (D10, 6 weeks, 3 months and 6 months)
02

Conditions studied

  • Ultrasound Therapy; Complications
  • Septic Arthritis
  • Knee Arthritis
03

In context

Arthritis, Infectious

123 studies on the registry are indexed under Arthritis, Infectious; 25 are open to participants now.

This study's planned enrollment of 30 is below the median of 100 across 72 observational studies indexed under Arthritis, Infectious.

Browse Arthritis, Infectious studies →

Lead sponsor

Poitiers University Hospital is the lead sponsor of 310 studies on the registry; 64 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with native septic arthritis of the knee

Inclusion criteria

  • Male or female of legal age
  • Bacteriologically proven native septic arthritis
  • Meets the definition of septic arthritis: Bacteriological documentation of joint puncture fluid-Native articulation
  • Free subject, without guardianship or trusteeship, or subordination
  • Non-opposition of the patient after clear and fair information about the study

Exclusion criteria

Exclusion Criteria:

  • Presence of material in the affected joint
  • Arthritis with Mycobacterium Tuberculosis.
  • Patients benefiting from a reinforced protection, namely: minors, pregnant and/or breast-feeding women, persons deprived of liberty by a judicial or administrative decision, adults under legal protection
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • native septic arthritis of the knee

    Describe the ultrasound abnormalities observed at D0, D10 or before surgery, 6 weeks, 3 months, 6 months, during native septic arthritis of the knee: thickness and vascularity of the synovial membrane, existence and measurement of joint effusion existence of articular partitioning, erosions and adjacent soft tissue involvement (muscle abscess, cellulitis)

    Device: ultrasound

Interventions

  • Deviceultrasound

    Describe the sonographic abnormalities observed at Day 0, Day 10, 6 weeks, 3 months, 6 months, during native septic arthritis of the knee

06

What researchers measure

Primary outcomes

  1. description of the ultrasound abnormalities seen in native septic arthritis of the knee

    Describe the ultrasonographic abnormalities seen in native septic arthritis of the knee

    Time frame: Day0, Day 10 or before surgery, 6week, 3months, 6months

07

Study locations

6 of 7 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04952220
Lead sponsor
Poitiers University Hospital
Responsible party
Sponsor
First posted
Jul 7, 2021
Start date
Oct 27, 2021
Primary completion
Apr 2025 (estimated)
Completion
Oct 2025 (estimated)
Last update
Jan 19, 2024

Study contacts

GERVAIS Elisabeth
Contact
elisabeth.gervais@chu-poitiers.fr
05 49 44 44 65
GERVAIS Elisabeth
principal investigator · Poitiers University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion